Arbutus Biopharma (ABUS)
(Real Time Quote from BATS)
$4.48 USD
+0.39 (9.54%)
Updated Sep 5, 2024 03:24 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Company Summary
Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.
Company Summary
General Information
Arbutus Biopharma Corporation
701 VETERANS CIRCLE
WARMINSTER, PA 18974
Phone: 267-469-0914
Fax: 604-419-3201
Web: http://www.arbutusbio.com
Email: ir@arbutusbio.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.10 |
Current Year EPS Consensus Estimate | -0.38 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 4.09 |
52 Week High | 4.42 |
52 Week Low | 1.69 |
Beta | 1.92 |
20 Day Moving Average | 886,647.31 |
Target Price Consensus | 4.75 |
4 Week | 16.52 |
12 Week | 25.85 |
YTD | 63.60 |
4 Week | 9.76 |
12 Week | 23.59 |
YTD | 41.37 |
Shares Outstanding (millions) | 188.78 |
Market Capitalization (millions) | 772.12 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $NA |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -10.00% |
vs. Previous Quarter | -10.00% |
vs. Previous Year | -62.89% |
vs. Previous Quarter | 12.66% |
Price/Book | 6.30 |
Price/Cash Flow | NA |
Price / Sales | 76.74 |
6/30/24 | -66.68 |
3/31/24 | -62.68 |
12/31/23 | -57.82 |
6/30/24 | -50.27 |
3/31/24 | -47.22 |
12/31/23 | -43.42 |
6/30/24 | 6.56 |
3/31/24 | 6.69 |
12/31/23 | 5.87 |
6/30/24 | 6.56 |
3/31/24 | 6.69 |
12/31/23 | 5.87 |
6/30/24 | -766.20 |
3/31/24 | -572.81 |
12/31/23 | -401.57 |
6/30/24 | -766.20 |
3/31/24 | -572.81 |
12/31/23 | -401.57 |
6/30/24 | -766.20 |
3/31/24 | -572.81 |
12/31/23 | -401.57 |
6/30/24 | 0.65 |
3/31/24 | 0.64 |
12/31/23 | 0.63 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |